Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Tirzepatide (TIRZ) is a metabolic peptide, at the fda approved stage in the published literature. Dual GIP/GLP-1 receptor agonist showing superior weight loss compared to GLP-1 agonists alone. Brand names include Mounjaro and Zepbound.
Dual GIP/GLP-1 receptor agonist showing superior weight loss compared to GLP-1 agonists alone. Brand names include Mounjaro and Zepbound.
| Research Status | FDA approved |
|---|---|
| Half-Life | ~5 days |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 2.5-15 mg weekly |
Activates both GIP and GLP-1 receptors for enhanced metabolic effects and greater weight loss.
Dual GIP/GLP-1 receptor agonist showing superior weight loss compared to GLP-1 agonists alone. Brand names include Mounjaro and Zepbound.
Activates both GIP and GLP-1 receptors for enhanced metabolic effects and greater weight loss.
Tirzepatide is at the following stage in the published literature: FDA approved. All information is for research and educational purposes only.
Reported half-life: ~5 days.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.